---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-015346"
form_type: "8-K"
ticker: "LIXT"
cik: "0001335105"
company_name: "LIXTE BIOTECHNOLOGY HOLDINGS, INC."
filed_at: "2025-06-17T23:59:59+00:00"
generated_at: "2026-05-19T04:25:27.204546+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lixte appoints Geordan Pursglove as CEO, contingent on Nasdaq financing by July 3

## Summary
- Geordan Pursglove appointed CEO and Chairman; Bastiaan van der Baan resigns as CEO, remains President and CSO.
- Employment agreement with Pursglove has $240K annual salary, plus potential bonus and stock option grant for 350K shares.
- Van der Baan's existing stock option for 250K shares fully vested; exercise period extended to one year after service ends.
- Pursglove's appointment automatically terminates if Lixte fails to complete a financing enabling Nasdaq listing by July 3, 2025.
- If financing condition not met, van der Baan to be reinstated as CEO and Chairman, and Pursglove's option grant cancelled.

## SEC filing metadata
- accession: 0001641172-25-015346
- form_type: 8-K
- ticker: LIXT
- cik: 0001335105
- company_name: LIXTE BIOTECHNOLOGY HOLDINGS, INC.
- filed_at: 2025-06-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1335105/000164117225015346/0001641172-25-015346-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1335105/000164117225015346/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-015346
- JSON: https://secwatch.observer/filing/0001641172-25-015346.json
- Plain text: https://secwatch.observer/filing/0001641172-25-015346.txt

## Key facts
- Executive change
  Bastiaan van der Baan departed as President and Chief Scientific Officer at LIXTE BIOTECHNOLOGY HOLDINGS, INC..
  - Action: resigned as Chairman and Chief Executive Officer
  - Role: President and Chief Scientific Officer
  source text: Bastiaan van der Baan resigned as Chairman of the Board of Directors and Chief Executive Officer
  evidence_url: https://www.sec.gov/Archives/edgar/data/1335105/000164117225015346/0001641172-25-015346-index.htm
- Executive change
  Geordan Pursglove was appointed as Chief Executive Officer and Chairman at LIXTE BIOTECHNOLOGY HOLDINGS, INC..
  - Action: appointed
  - Role: Chief Executive Officer and Chairman
  source text: effective June 16, 2025, Geordan Pursglove was appointed as the Company’s Chairman of the Board of Directors and Chief Executive Officer,
  evidence_url: https://www.sec.gov/Archives/edgar/data/1335105/000164117225015346/0001641172-25-015346-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.